Immunomedics Stock Price - IMMU

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 15.44 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Immunomedics Inc IMMU NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.42 -2.65% 15.44 15.86 14.86 15.74 15.86 20:00:00
Bid Price Ask Price Spread Spread % News
12.20 18.00 5.80 32.22% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
9,590 1,841,308 $ 15.34 $ 28,237,806 2,782,499 11.59 - 24.99
Last Trade Time Type Quantity Stock Price Currency
16:46:08 formt 3,143 $ 15.44 USD

Immunomedics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.96B 191.98M $ -157.67M -1.75 - 189.67M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 13.00 1.20%

more financials information »

Immunomedics News

Loading Messages....

Latest IMMU Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IMMU Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week14.2515.9813.9314.67432M1.198.35%
1 Month17.0117.2512.0514.40483M-1.57-9.23%
3 Months15.0317.50612.0514.61472M0.412.73%
6 Months16.717.50611.5914.36462M-1.26-7.54%
1 Year22.524.9911.5915.73233M-7.06-31.38%
3 Years2.2727.332.0213.24223M13.17580.18%
5 Years3.6527.331.510.88602M11.79323.01%

Immunomedics Description

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.